logo
Ziff Davis Reports Second Quarter 2025 Financial Results and Reaffirms 2025 Guidance

Ziff Davis Reports Second Quarter 2025 Financial Results and Reaffirms 2025 Guidance

Business Wire4 days ago
NEW YORK--(BUSINESS WIRE)--Ziff Davis, Inc. (NASDAQ: ZD) ('Ziff Davis' or 'the Company') today reported unaudited financial results for the second quarter ended June 30, 2025.
'We are very pleased with our second quarter results, which exceeded expectations and marked our strongest quarterly revenue growth since 2021,' said Vivek Shah, Chief Executive Officer of Ziff Davis. 'Our new segment reporting is providing greater transparency into the intrinsic value of our key businesses, including breakthrough results from our Connectivity and Health & Wellness businesses.'
SECOND QUARTER 2025 RESULTS
Q2 2025 quarterly revenues increased 9.8% to $352.2 million compared to $320.8 million for Q2 2024.
Income from operations increased 17.2% to $33.5 million compared to $28.6 million for Q2 2024.
Net income (1) decreased to $26.3 million compared to $36.9 million for Q2 2024.
Net income per diluted share (1) decreased to $0.62 in Q2 2025 compared to $0.77 for Q2 2024.
Adjusted EBITDA (2) for the quarter increased 11.8% to $107.7 million compared to $96.3 million for Q2 2024.
Adjusted net income (2) decreased to $51.6 million compared to $53.7 million for Q2 2024.
Adjusted net income per diluted share (1)(2) (or 'Adjusted diluted EPS') for the quarter increased 5.1% to $1.24 compared to $1.18 for Q2 2024.
Net cash provided by operating activities was $57.1 million in Q2 2025 compared to $50.6 million in Q2 2024. Free cash flow (2) was $26.9 million in Q2 2025 compared to $25.1 million in Q2 2024.
Ziff Davis deployed approximately $11.4 million for current and prior year acquisitions during the quarter and $33.9 million related to share repurchases in Q2 2025.
The following table reflects results for the three and six months ended June 30, 2025 and 2024, respectively (in millions, except per share amounts).
Notes:
(1)
GAAP effective tax rates were approximately 16.8% and 19.9% for the three months ended June 30, 2025 and 2024, respectively, and 24.9% and 27.9% for the six months ended June 30, 2025 and 2024, respectively. Adjusted effective tax rates were approximately 24.6% and 23.3% for the three months ended June 30, 2025 and 2024, respectively, and 24.2% and 23.6% for the six months ended June 30, 2025 and 2024, respectively.
(2)
For definitions of non-GAAP financial measures and reconciliations of GAAP to non-GAAP financial measures refer to section 'Non-GAAP Financial Measures' further in this release.
(3)
The revenues associated with each of the reportable segments may not foot precisely since each is presented independently.
(4)
Prior period segment information is presented on a comparable basis to conform to our new segment presentation with no effect on previously reported consolidated results.
Expand
ZIFF DAVIS GUIDANCE
The Company reaffirms its guidance for fiscal year 2025 as follows (in millions, except per share data):
____________________
(1)
It is anticipated that the Adjusted effective tax rate for 2025 will be between 23.25% and 25.25%.
Expand
A reconciliation of forward-looking Adjusted EBITDA and Adjusted diluted EPS to the corresponding GAAP financial measures is not available without unreasonable effort due primarily to variability and difficulty in making accurate forecasts and projections of certain non-operating items such as (Gain) loss on investments, net, Other (income) loss, net, and other unanticipated items that may arise in the future.
EARNINGS CONFERENCE CALL AND AUDIO WEBCAST
Ziff Davis will host a live audio webcast and conference call discussing its second quarter 2025 financial results on Thursday, August 7, 2025, at 8:30AM ET. The live webcast and call will be accessible by phone by dialing (844) 985-2014 or via www.ziffdavis.com. Following the event, the audio recording and presentation materials will be archived and made available at www.ziffdavis.com.
ABOUT ZIFF DAVIS
Ziff Davis, Inc. (NASDAQ: ZD) is a vertically focused digital media and internet company whose portfolio includes leading brands in technology, shopping, gaming and entertainment, health and wellness, connectivity, cybersecurity, and martech. For more information, visit www.ziffdavis.com.
'Safe Harbor' Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including those contained in Vivek Shah's quote, and the 'Ziff Davis Guidance' section regarding the Company's expected fiscal 2025 financial performance. These forward-looking statements are based on management's current expectations or beliefs and are subject to numerous assumptions, risks, and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These factors and uncertainties include, among other items: the Company's ability to grow advertising, licensing, and subscription revenues, profitability, and cash flows, particularly in light of an uncertain U.S. or worldwide economy, including the possibility of economic downturn or recession; the Company's ability to make interest and debt payments; the Company's ability to identify, close, and successfully transition acquisitions; customer growth and retention; the Company's ability to create compelling content; our reliance on third-party platforms; the threat of content piracy and developments related to artificial intelligence; increased competition and rapid technological changes; variability of the Company's revenue based on changing conditions in particular industries and the economy generally; protection of the Company's proprietary technology or infringement by the Company of intellectual property of others; the risk of losing critical third-party vendors or key personnel; the risks associated with fraudulent activity, system failure, or a security breach; risks related to our ability to adhere to our internal controls and procedures; the risk of adverse changes in the U.S. or international regulatory environments, including but not limited to the imposition or increase of taxes or regulatory-related fees; the risks related to supply chain disruptions, increased tariffs and trade protection measures, inflationary conditions, and rising interest rates; the risk of liability for legal and other claims; and the numerous other factors set forth in Ziff Davis' filings with the Securities and Exchange Commission ('SEC'). For a more detailed description of the risk factors and uncertainties affecting Ziff Davis, refer to our most recent Annual Report on Form 10-K and the other reports filed by Ziff Davis from time-to-time with the SEC, each of which is available at www.sec.gov. The forward-looking statements provided in this press release, including those contained in Vivek Shah's quote and in the 'Ziff Davis Guidance' portion regarding the Company's expected fiscal 2025 financial performance are based on limited information available to the Company at this time, which is subject to change. Although management's expectations may change after the date of this press release, the Company undertakes no obligation to revise or update these statements.
Three months ended June 30,
Six months ended June 30,
2025
2024
2025
2024
Total revenues
$
352,209
$
320,800
$
680,845
$
635,285
Operating costs and expenses:
Direct costs
48,974
50,024
96,182
95,911
Sales and marketing
141,598
124,766
269,278
241,766
Research, development, and engineering
16,478
16,795
32,354
34,569
General, administrative, and other related costs
54,070
48,505
100,980
98,015
Depreciation and amortization
57,606
52,141
113,438
100,594
Total operating costs and expenses
318,726
292,231
612,232
570,855
Income from operations
33,483
28,569
68,613
64,430
Interest expense, net
(6,523
)
(1,804
)
(12,654
)
(3,573
)
Loss on sale of businesses



(3,780
)
Gain (loss) on investments, net
4,340
3,051
4,340
(7,654
)
Other (loss) income, net
(5,786
)
5,267
(8,589
)
5,163
Income before income tax expense and income from equity method investment
25,514
35,083
51,710
54,586
Income tax expense
(4,286
)
(6,990
)
(12,873
)
(15,221
)
Income from equity method investment, net of tax
5,115
8,817
11,745
8,172
Net income
$
26,343
$
36,910
$
50,582
$
47,537
Net income per common share:
Basic
$
0.63
$
0.81
$
1.20
$
1.04
Diluted
$
0.62
$
0.77
$
1.19
$
1.02
Weighted average shares outstanding:
Basic
41,732,800
45,492,809
42,143,165
45,676,726
Expand
ZIFF DAVIS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED, IN THOUSANDS)
Six months ended June 30,
2025
2024
Cash flows from operating activities:
Net income
$
50,582
$
47,537
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
113,438
100,594
Non-cash operating lease costs
4,325
5,538
Share-based compensation
21,479
20,472
Provision for credit losses on accounts receivable
1,012
1,336
Deferred income taxes, net
(7,320
)
(7,869
)
Loss on sale of businesses

3,780
Changes in fair value of contingent consideration
(2,318
)

Income from equity method investments, net
(11,745
)
(8,172
)
(Gain) loss on investments, net
(4,340
)
7,654
Other
1,701
1,779
Decrease (increase) in:
Accounts receivable
147,417
44,215
Prepaid expenses and other current assets
(523
)
(9,138
)
Other assets
1,900
(375
)
Increase (decrease) in:
Accounts payable
(231,065
)
(80,548
)
Deferred revenue
464
13,108
Accrued liabilities and other current liabilities
(7,320
)
(13,789
)
Net cash provided by operating activities
77,687
126,122
Cash flows from investing activities:
Purchases of property and equipment
(55,752
)
(53,633
)
Acquisitions, net of cash received
(50,345
)
(56,698
)
Distribution from equity method investment
9,196

Proceeds from sale of equity investments
25,250
19,455
Proceeds from sale of businesses, net of cash divested

7,860
Other
51
(124
)
Net cash used in investing activities
(71,600
)
(83,140
)
Cash flows from financing activities:
Repurchase of common stock
(68,834
)
(87,928
)
Issuance of common stock under employee stock purchase plan
3,751
4,525
Deferred payments for acquisitions
(213
)
(7,417
)
Other
(1,592
)
(940
)
Net cash used in financing activities
(66,888
)
(91,760
)
Effect of exchange rate changes on cash and cash equivalents
12,180
(1,600
)
Net change in cash and cash equivalents
(48,621
)
(50,378
)
Cash and cash equivalents at beginning of period
505,880
737,612
Cash and cash equivalents at end of period
$
457,259
$
687,234
Expand
Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ('GAAP'), we use the following non-GAAP financial measures: Adjusted EBITDA, Adjusted EBITDA margin, Adjusted net income (loss), Adjusted net income (loss) per diluted share, Free cash flow, and Adjusted effective tax rate (collectively the 'non-GAAP financial measures'). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.
We use these non-GAAP financial measures for financial and operational decision making and as means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and liquidity by excluding certain items that may not be indicative of our recurring core business operating results or, in certain cases, may be non-cash in nature. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance and liquidity. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making, (2) certain measures are used to determine the amount of annual incentive compensation paid to our named executive officers, and (3) they are used by the analyst community to help them analyze the health of our business.
These non-GAAP financial measures are not measures presented in accordance with GAAP, and our use of these terms may vary from that of other companies, limiting their usefulness for comparison purposes. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations determined in accordance with GAAP.
Non-GAAP financial measures exclude the certain items listed below. We believe that excluding these items from the non-GAAP measures facilitates comparisons to historical operating results and comparisons to peers, many of which exclude similar items. We believe that non-GAAP financial measures provide meaningful supplemental information regarding operational performance. We further believe these measures are useful to investors in that they allow for greater transparency of certain line items in the Company's financial statements.
Adjusted EBITDA is defined as Net income (loss) with adjustments to reflect the addition or elimination of certain items including, but not limited to:
Interest expense, net. Interest expense is generated primarily from interest due on outstanding debt, partially offset by interest income generated from the interest earned on cash, cash equivalents, and investments;
(Gain) loss on debt extinguishment, net. This is a non-cash expense that relates to extinguishments of long-term debt obligations. We believe this (gain) loss does not represent recurring core business operating results of the Company;
(Gain) loss on sale of businesses. This gain or loss relates to the sales of businesses and does not represent recurring core business operating results of the Company;
(Gain) loss on investments, net. This item includes realized gains and losses, unrealized gains and losses, and impairment charges on debt and equity investments. The amount of gain or loss depends on the share price for investments with readily determinable fair value and on observable price changes for investments without a readily determinable fair value, and does not represent core business operating results of the Company;
Other (income) loss, net. This income or expense relates to other non-operating items and does not represent recurring core business operating results of the Company;
Income tax (benefit) expense. This benefit or expense depends on the pre-tax loss or income of the Company, statutory tax rates, tax regulations, and different tax rates in various jurisdictions in which the Company operates and which the Company does not have the control over;
(Income) loss from equity method investment, net of tax. This is a non-cash income or expense as it relates primarily to our investment in OCV Fund I, LP (the 'OCV Fund'). We believe that gain or loss resulting from our equity method investment does not represent core business operating results of the Company;
Depreciation and amortization. This is a non-cash expense at it relates to use and associated reduction in value of certain assets including equipment, fixtures, and certain capitalized internal-use software and website development costs, and identifiable definite-lived intangible assets of the acquired businesses;
Share-based compensation. This is a non-cash expense as it relates to awards granted under the various share-based incentive plans of the Company. We view the economic cost of share-based awards to be the dilution to our share base;
Acquisition, integration, and other costs. This includes adjustments to contingent consideration, lease terminations, retention bonuses, other acquisition-specific items, and other costs, such as severance, third-party debt modification costs, litigation costs from discrete, complex, or unusual proceedings, and legal settlements. These expenses do not represent core business operating results of the Company;
Disposal related costs. These are expenses associated with the disposal of certain businesses that do not represent core business operating results of the Company;
Lease asset impairments and other charges. These expenses are incurred in connection with impaired right-of-use ('ROU') assets of the Company. Associated expenses are comprised of insurance, utility, and other charges related to assets that are no longer in use, and partially offset by the sublease income earned. These expenses do not represent core business operating results of the Company; and
Goodwill impairment. This is a non-cash expense that is recorded when the carrying value of the reporting unit exceeds its fair value and does not represent core business operating results of the Company.
Adjusted EBITDA margin is calculated by dividing Adjusted EBITDA by Total Revenues.
Adjusted net income (loss) is defined as Net income (loss) with adjustments to reflect the addition or elimination of certain statement of operations items including, but not limited to:
Interest, net. This reflects the difference between the imputed and coupon interest expense associated with the 4.625% Senior Notes and a charge that the Company determined to be penalty interest associated with the 1.75% Convertible Notes, offset in part by a certain interest income earned by the Company. These net expenses do not represent core business operating results of the Company;
(Gain) loss on debt extinguishment, net. This is a non-cash expense that relates to extinguishments of long-term debt obligations. We believe this gain or loss does not represent recurring core business operating results of the Company;
(Gain) loss on sale of businesses. This gain or loss relates to the sales of businesses and does not represent recurring core business operating results of the Company;
(Gain) loss on investments, net. This item includes realized gains and losses, unrealized gains and losses, and impairment charges on debt and equity investments. The amount of gain or loss depends on the share price for investments with readily determinable fair value and on observable price changes for investments without a readily determinable fair value, and does not represent core business operating results of the Company;
(Income) loss from equity method investment, net of tax. This is a non-cash income or expense as it relates primarily to our investment in the OCV Fund. We believe that gains or losses resulting from our equity method investment do not represent core business operating results of the Company;
Amortization. Includes the amortization of patents and intangible assets that we acquired. This is a non-cash expense as it primarily relates to identifiable definite-lived intangible assets of the acquired businesses. We believe that acquired intangible assets represent cost incurred by the acquiree to build value prior to the acquisition and the amortization of this cost does not represent core business operating results of the Company;
Share-based compensation. This is a non-cash expense as it relates to awards granted under the various share-based incentive plans of the Company. We view the economic cost of share-based awards to be the dilution to our share base;
Acquisition, integration, and other costs. This includes adjustments to contingent consideration, lease terminations, retention bonuses, other acquisition-specific items, and other costs, such as severance, third-party debt modification costs, litigation costs from discrete, complex, or unusual proceedings, and legal settlements. These expenses do not represent core business operating results of the Company;
Disposal related costs. These are expenses associated with the disposal of certain businesses that do not represent core business operating results of the Company;
Lease asset impairments and other charges. These expenses are incurred in connection with impaired ROU assets of the Company. Associated expenses are comprised of insurance, utility, and other charges related to assets that are no longer in use, and partially offset by the sublease income earned. These expenses do not represent core business operating results of the Company; and
Goodwill impairment. This is a non-cash expense that is recorded when the carrying value of the reporting unit exceeds its fair value and does not represent core business operating results of the Company.
Adjusted net income (loss) per diluted share is calculated by dividing Adjusted net income (loss) by the diluted weighted average shares of common stock outstanding excluding the effect of convertible debt dilution.
Free cash flow is defined as Net cash provided by operating activities, less purchases of property and equipment, plus changes in contingent consideration (if any).
Adjusted effective tax rate is calculated based upon the GAAP effective tax rate with adjustments for the tax applicable to non-GAAP adjustments to Net income (loss), generally based upon the effective marginal tax rate of each adjustment.
The following table sets forth a reconciliation of Net income to Adjusted EBITDA:
Three months ended June 30,
Six months ended June 30,
2025
2024
2025
2024
Net income
$
26,343
$
36,910
$
50,582
$
47,537
Interest expense, net
6,523
1,804
12,654
3,573
Loss on sale of businesses



3,780
(Gain) loss on investment, net
(4,340
)
(3,051
)
(4,340
)
7,654
Other loss (income), net
5,786
(5,267
)
8,589
(5,163
)
Income tax expense
4,286
6,990
12,873
15,221
Income from equity method investment, net of tax
(5,115
)
(8,817
)
(11,745
)
(8,172
)
Depreciation and amortization
57,606
52,141
113,438
100,594
Share-based compensation
11,727
11,600
21,479
20,472
Acquisition, integration, and other costs
3,987
3,837
3,430
10,103
Disposal related costs

77
1
573
Lease asset impairments and other charges
851
40
871
843
Adjusted EBITDA
$
107,654
$
96,264
$
207,832
$
197,015
Expand
Three months ended June 30, 2024
Technology &
Shopping
Gaming &
Entertainment
Health &
Wellness
Connectivity
Cybersecurity &
Martech
Corporate (1)
Total
(Loss) income from operations
$
(8,067
)
$
8,198
$
13,302
$
21,702
$
11,547
$
(18,113
)
$
28,569
Depreciation and amortization
19,863
2,841
13,013
7,617
8,800
7
52,141
Share-based compensation
1,625
327
1,509
764
1,222
6,153
11,600
Acquisition, integration, and other costs
4,086
916
2,276
(5,923
)
471
2,011
3,837
Disposal related costs




20
57
77
Lease asset impairments and other charges
(162
)

15

105
82
40
Adjusted EBITDA
$
17,345
$
12,282
$
30,115
$
24,160
$
22,165
$
(9,803
)
$
96,264
Expand
____________________
Figures above are net of inter-segment revenues and operating costs and expenses. Prior period segment information is presented on a comparable basis to conform to our new segment presentation with no effect on previously reported consolidated results.
(1) Corporate includes certain unallocated overhead costs that were historically presented within the Digital Media reportable segment.
Expand
The following tables set forth a reconciliation of Net income to Adjusted net income with adjustments presented on after-tax basis:
Three months ended June 30,
2025
Per diluted
share (1)
2024
Per diluted
share (1)
Net income
$
26,343
$
0.62
$
36,910
$
0.77
Interest, net
61

17

Gain on sale of businesses


(3,668
)
(0.08
)
Gain on investments, net
(4,340
)
(0.10
)
(2,591
)
(0.06
)
Income from equity method investment, net of tax
(5,115
)
(0.12
)
(8,817
)
(0.19
)
Amortization
23,183
0.56
21,179
0.47
Share-based compensation
7,842
0.19
9,421
0.21
Acquisition, integration, and other costs
3,002
0.07
1,214
0.03
Disposal related costs


60

Lease asset impairment and other charges
656
0.02
14

Dilutive effect of the convertible debt



0.03
Adjusted net income
$
51,632
$
1.24
$
53,739
$
1.18
Expand
Six months ended June 30,
2025
Per diluted share (1)
2024
Per diluted share (1)
Net income
$
50,582
$
1.19
$
47,537
$
1.02
Interest, net
122

12

Loss on sale of business


112

(Gain) loss on investments, net
(4,340
)
(0.10
)
7,077
0.15
Income from equity method investment, net
(11,745
)
(0.28
)
(8,172
)
(0.18
)
Amortization
45,051
1.07
41,264
0.90
Share-based compensation
17,658
0.42
17,207
0.38
Acquisition, integration and other costs
2,560
0.06
6,085
0.13
Disposal related costs
1

432
0.01
Lease asset impairment and other charges
683
0.02
657
0.01
Dilutive effect of the convertible debt



0.03
Adjusted net income
$
100,572
$
2.38
$
112,211
$
2.45
Expand
____________________
(1) The reconciliation of Net income per diluted share to Adjusted net income per diluted share may not foot since each is calculated independently.
Expand
The following are the adjustments to certain statement of operations items used to derive Adjusted net income, which we believe provide useful information about our operating results and enhance the overall understanding of past financial performance and future prospects of the Company.
Three months ended June 30, 2025
GAAP
amount
Adjustments
Adjusted
non-GAAP
amount
Interest, net
(Gain) loss on
sale of
business
(Gain) loss on
investments,
net
(Income) loss
from equity
method
investments,
net
Amortization
Share-based
compensation
Acquisition,
integration, and
other costs
Disposal
related costs
Lease asset
impairments
and other
charges
Direct costs
$
(48,974
)
$

$

$

$

$

$
68
$
(6
)
$

$

$
(48,912
)
Sales and marketing
$
(141,598
)





1,349
1,237


$
(139,012
)
Research, development, and engineering
$
(16,478
)





937
303


$
(15,238
)
General, administrative, and other related costs
$
(54,070
)





9,373
2,453

851
$
(41,393
)
Depreciation and amortization
$
(57,606
)




30,658




$
(26,948
)
Interest expense, net
$
(6,523
)
82








$
(6,441
)
Gain on investments, net
$
4,340


(4,340
)






$

Other loss, net
$
(5,786
)









$
(5,786
)
Income tax expense (1)
$
(4,286
)
(21
)



(7,475
)
(3,885
)
(985
)

(195
)
$
(16,847
)
Income from equity method investment, net of tax
$
5,115



(5,115
)





$

Total non-GAAP adjustments
$
61
$

$
(4,340
)
$
(5,115
)
$
23,183
$
7,842
$
3,002
$

$
656
Expand
____________________
(1)
Adjusted effective tax rate was approximately 24.6% for the three months ended June 30, 2025. The calculation is based on a ratio where the numerator is the adjusted income tax expense of $16,847 and the denominator is $68,479, which equals adjusted net income of $51,632 plus adjusted income tax expense.
Expand
Three months ended June 30, 2024
GAAP
amount
Adjustments
Adjusted
non-GAAP
amount
Interest, net
(Gain) loss on
sale of
business
(Gain) loss on
investments,
net
(Income) loss
from equity
method
investments,
net
Amortization
Share-based
compensation
Acquisition,
integration, and
other costs
Disposal
related costs
Lease asset
impairments
and other
charges
Direct costs
$
(50,024
)
$

$

$

$

$

$
62
$
101
$

$

$
(49,861
)
Sales and marketing
$
(124,766
)





1,093
1,949


$
(121,724
)
Research, development, and engineering
$
(16,795
)





1,071
1,271


$
(14,453
)
General, administrative, and other related costs
$
(48,505
)





9,374
516
77
40
$
(38,498
)
Depreciation and amortization
$
(52,141
)




27,856




$
(24,285
)
Interest expense, net
$
(1,804
)
23








$
(1,781
)
Gain on investments, net
$
3,051


(3,051
)






$

Other income, net
$
5,267

(4,890
)




(537
)


$
(160
)
Income tax expense (1)
$
(6,990
)
(6
)
1,222
460

(6,677
)
(2,179
)
(2,086
)
(17
)
(26
)
$
(16,299
)
Income from equity method investment, net of tax
$
8,817



(8,817
)





$

Expand
____________________
(1)
Adjusted effective tax rate was approximately 23.3% for the three months ended June 30, 2024. The calculation is based on a ratio where the numerator is the adjusted income tax expense of $16,299 and the denominator is $70,037, which equals adjusted net income of $53,739 plus adjusted income tax expense.
Expand
Six months ended June 30, 2025
GAAP
amount
Adjustments
Adjusted
non-GAAP
amount
Interest, net
(Gain) loss on
sale of
business
(Gain) loss on
investments,
net
(Income) loss
from equity
method
investments,
net
Amortization
Share-based
compensation
Acquisition,
integration, and
other costs
Disposal
related costs
Lease asset
impairments
and other
charges
Direct costs
$
(96,182
)
$

$

$

$

$

$
131
$
60
$

$

$
(95,991
)
Sales and marketing
$
(269,278
)





2,335
2,219


$
(264,724
)
Research, development, and engineering
$
(32,354
)





1,727
238


$
(30,389
)
General, administrative, and other related costs
$
(100,980
)





17,286
913
1
871
$
(81,909
)
Depreciation and amortization
$
(113,438
)




59,449




$
(53,989
)
Interest expense, net
$
(12,654
)
163








$
(12,491
)
Gain on investments, net
$
4,340


(4,340
)






$

Other loss, net
$
(8,589
)









$
(8,589
)
Income tax expense (1)
$
(12,873
)
(41
)



(14,398
)
(3,821
)
(870
)

(188
)
$
(32,191
)
Income from equity method investment, net
$
11,745



(11,745
)





$

Expand
Six months ended June 30, 2024
GAAP
amount
Adjustments
Adjusted
non-GAAP
amount
Interest, net
(Gain) loss on
sale of
business
(Gain) loss on
investments,
net
(Income) loss
from equity
method
investments,
net
Amortization
Share-based
compensation
Acquisition,
integration, and
other costs
Disposal
related costs
Lease asset
impairments
and other
charges
Direct costs
$
(95,911
)
$

$

$

$

$

$
123
$
271
$

$

$
(95,517
)
Sales and marketing
$
(241,766
)





1,851
2,490


$
(237,425
)
Research, development, and engineering
$
(34,569
)





2,161
1,494
40

$
(30,874
)
General, administrative, and other related costs
$
(98,015
)





16,337
5,848
533
843
$
(74,454
)
Depreciation and amortization
$
(100,594
)




54,280




$
(46,314
)
Interest expense, net
$
(3,573
)
16








$
(3,557
)
Loss on sale of business
$
(3,780
)

3,780







$

Loss on investments, net
$
(7,654
)


7,654






$

Other income, net
$
5,163

(4,890
)




(537
)


$
(264
)
Income tax expense (1)
$
(15,221
)
(4
)
1,222
(577
)

(13,016
)
(3,265
)
(3,481
)
(141
)
(186
)
$
(34,669
)
Income from equity method investment, net
$
8,172



(8,172
)





$

Total non-GAAP adjustments
$
12
$
112
$
7,077
$
(8,172
)
$
41,264
$
17,207
$
6,085
$
432
$
657
Expand
____________________
(1)
Adjusted effective tax rate was approximately 23.6% for the six months ended June 30, 2024. The calculation is based on a ratio where the numerator is the adjusted income tax expense of $34,669 and the denominator is $146,880, which equals adjusted net income of $112,211 plus adjusted income tax expense.
Expand
ZIFF DAVIS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(UNAUDITED, IN THOUSANDS)
The following tables set forth a reconciliation of Net cash provided by operating activities to Free cash flow:
2025
Q1
Q2
Q3
Q4
YTD
Net cash provided by operating activities
$
20,613
$
57,074
$

$

$
77,687
Less: Purchases of property and equipment
(25,619
)
(30,133
)


(55,752
)
Free cash flow
$
(5,006
)
$
26,941
$

$

$
21,935
Expand
Expand
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UBS Remains a Buy on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)
UBS Remains a Buy on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)

Business Insider

time16 minutes ago

  • Business Insider

UBS Remains a Buy on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (GQG)

In a report released today, Shreyas Patel CFA from UBS maintained a Buy rating on GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh, with a price target of A$2.65. The company's shares closed last Friday at A$1.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Patel CFA covers the Financial sector, focusing on stocks such as GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh, Magellan Financial Group Ltd, and HUB24 Limited. According to TipRanks, Patel CFA has an average return of 11.8% and a 68.09% success rate on recommended stocks. In addition to UBS, GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh also received a Buy from Morgan Stanley's Andrei Stadnik in a report issued on July 30. However, on July 29, Morgans downgraded GQG Partners, Inc. Shs Chess Depository Interests Repr 1 Sh (ASX: GQG) to a Hold.

‘Make a Fast Exit,' Says Top Investor About Palantir Stock
‘Make a Fast Exit,' Says Top Investor About Palantir Stock

Business Insider

time36 minutes ago

  • Business Insider

‘Make a Fast Exit,' Says Top Investor About Palantir Stock

Some companies are riding the AI wave — and then there's Palantir (NASDAQ:PLTR) stock, practically surfing it into the stratosphere with a whopping 538% gain over the past year. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That surge has been fueled by results that keep smashing expectations. In its Q2 2025 earnings release last week, Palantir not only crossed the $1 billion revenue mark for the first time, but also showed no signs that its white-hot momentum is cooling. While defense-related government contracts remain its bread and butter, U.S. commercial revenue soared 93%, underscoring that PLTR is firing on all cylinders. But eye-popping numbers can also draw sharp scrutiny. One top investor, known by the pseudonym JR Research, warns that the growth party may be nearing its peak – and that overoptimistic bulls could be in for a harsh reality check. 'With PLTR's growth rate potentially peaking this year, the market momentum could reverse to the downside, ensnaring the overoptimistic bulls,' who is among the very top 1% of TipRanks' stock pros. JR acknowledges the company's strong fundamentals, including a recent $10 billion, 10-year deal with the U.S. Army, but questions whether Wall Street's sky-high expectations are sustainable. With valuations approaching a staggering 250x P/E, JR suggests the stock's rally assumes a 'never-ending' pace of growth, which he doubts is realistic. 'Don't you think that when the chickens come home to roost, the pain might also be as equally 'intense' as the excitement that was felt on the way up?' the investor asks, advising both current and would-be investors to tread carefully, or consider exiting altogether. (To watch JR Research's track record, click here) Wall Street isn't as blunt, but skepticism is still in the air. The consensus rating sits at Hold, with 13 analysts on the sidelines versus just 4 Buys and 2 Sells. The average 12-month price target of $152.12 implies ~19% downside from current levels. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Yahoo

time38 minutes ago

  • Yahoo

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Press Releases | Nyxoah Investors Revenue for the second quarter of 2025 is anticipated to be approximately €1.3 million, a 73% increase over the second quarter of 2024. Operating expenses for the second quarter of 2025 are anticipated to be approximately €20.7 million, a 50% increase over the second quarter of 2024. Cash, cash equivalents and financial assets are anticipated to be approximately €43.0 million at June 30, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones. The Company expects to close patient enrollment in its ACCCESS clinical trial prior to enrolling all 106 potential patients. The study will continue, with the patients currently enrolled, with the co-primary endpoints, Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) responder rates, assessed at 12 months post implant and followed for five years. The Company reorganized its global R&D function and expects to transition all ongoing R&D activities from Israel to the U.S. and Belgium. The Company received notice that Inspire Medical Systems, Inc. ('Inspire') filed a lawsuit against the Company in the United States alleging infringement of certain patents owned by Inspire. The Company is well prepared, has the means and intends to vigorously defend itself in this matter. 'We are pleased with the growth we saw in the second quarter, which provides further evidence that our commercial proof of concept in Germany has been successful,' commented Olivier Taelman, Chief Executive Officer. 'With FDA approval in hand, we expect to take the lessons learned from Germany and apply them to the U.S. as we bring our unique Genio system to the U.S. In addition, we believe that the patient population currently enrolled in the ACCCESS study will provide statistically significant results, which along with the outcomes from prior clinical evidence, will provide meaningful data with respect to the safety and efficacy of using Genio therapy in the patient population suffering from Complete Concentric Collapse ('CCC'). Patients with CCC represent a significant unmet need in the treatment of OSA as no FDA approved treatment currently exists.' The preliminary, unaudited financial results described in this press release, including preliminary revenue and operating expenses for the second quarter of 2025 and preliminary cash, cash equivalents and financial assets as of June 30, 2025, are estimates only. These financial results could change as a result of further review. Accordingly, you should not place undue reliance on this information. Complete financial results for the second quarter of 2025 will be announced and issued on Monday, August 18, 2025 after NASDAQ market close. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the U.S. Food and Drug Administration (FDA) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. For more information, please visit Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. FORWARD-LOOKING STATEMENTS Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Company's financial results for the second quarter ended June 30, 2025; the Company's estimates of revenue and operating expenses for the second quarter of 2025 and cash, cash equivalents and financial assets as of June 30, 2025; the Genio system; planned and ongoing clinical studies of the Genio system, including the ACCCESS study; the potential advantages of the Genio system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's plans to transition its ongoing R&D activities to the U.S. and Belgium; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press NyxoahJohn Landry, CFOIR@ For MediaIn United StatesFINN Partners – Alyssa Paldo In International/GermanyMC Services – Anne Hennecke nyxoah@ In Belgium/FranceBackstage Communication – Gunther De Backer gunther@ 531708903v.1 Attachment Preliminary Results 2Q and 1st Half 25 PR-531708903-v5Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store